IGF1 and liver disorder: We therefore matched a third control dataset to the LOLA patients based on sarcopenia diagnosis only for this analysis (irrespective of liver disease) that still showed significantly higher levels of IGF-1 compared to the LOLA group (93.1 ± 51.1 versus 48.3 ± 28.1 ng/mL, p = 0.01), indicating the close connection of hepatic encephalopathy to muscle metabolism in cirrhosis.